Important legal notice
   
Contact   |   Search   

Sixth Framework Programme LIFE SCIENCES, GENOMICS AND BIOTECHNOLOGY FOR HEALTH
(for more information visit the website)

  FP6 MAJOR PROJECTS LIBRARY  
 

The library contains an overview of Integrated Projects (IPs) and Networks of Excellence (NoEs) selected so far. The What's New? section features projects with new information such as links to websites, articles etc.

NB: The library does not yet include Information Society Technologies, or the parts of Aeronautics and Space, and Sustainable Surface Transport covered by the Energy and Transport DG.

Click a title below and then scroll down the page to see projects for that thematic priority.

Major Projects Library Home Page
Number of projects in the library
 
IPs
NoEs
Life sciences, genomics and biotechnologies for health
56
21
Nanotechnologies and nanoscience, knowledge-based multifunctional materials, and new production processes and devices
14
17
Aeronautics and space
8
2
Food quality and safety
16
6
Sustainable energy systems
14
4
Sustainable surface transport
8
4
Global change and ecosystems
10
4
Citizens and governance in a knowledge-based society
2
3
 
European Atomic Energy Community - Euratom
6
2
 
TOTAL
134
63
WHAT'S NEW?  (3 of 3)
Project: Genomics, mechanisms and treatment of addiction
Acronym:   GENADDICT
What's new:   New project
Go to project ...
Project: Curing autoimmune disease. A translational approcah to autoimmune diseases in the post-genomic era using inflammatory arthritis and myositis as prototypes and learning examples.
Acronym:   AUTOCURE
What's new:   New project
Go to project ...
Project: Task-force in Europe for Drug Development for the Young
Acronym:   TEDDY
What's new:   New project
Go to project ...
DISPLAY OPTIONS
Display all updated projects for: LIFE SCIENCES, GENOMICS AND BIOTECHNOLOGY FOR HEALTH

Display all updated projects for all thematic priorities

Go to list of Integrated Projects (IPs) and Networks of Excellence (NoEs)

Find Calls for Proposals on CORDIS


SEARCH

To search project titles, acronyms and summaries within this theme for a specific word (or part of a word), type it in the box and click the submit button. (To search across all themes, use the search on the Major Projects Library home page.)

   

Example: to find projects mentioning "genome", "genomes", "genomics" etc. type "genom" (without quotation marks). Multiple words will be searched for together; e.g. "cancer or diabetes" will find only those projects which contain that exact text.

  INTEGRATED PROJECTS (2)  
Title: Curing autoimmune disease. A translational approcah to autoimmune diseases in the post-genomic era using inflammatory arthritis and myositis as prototypes and learning examples.
Acronym:   AUTOCURE
What's new:   New project
Project summary:   Objective: To transform knowledge obtained from molecular research particularly within genomics, into a cure in an increasing number of patients suffering from inflammatory rheumatic diseases. Rheumatoid arthritis (RA) is used as a prototype since this disease offers unique opportunities to define and evaluate new therapies. State of the art and beyond: Development of the first generation of targeted therapies (anti-TNF and anti-IL-1) in chronic inflammatory disease used RA as the prototype disease after work from European investigators included in the current IP. This work demonstrated (i) that targeted therapies can be efficient and (ii) that cure is still not achieved, but is within reach through a strong international consortium covering translational research and molecular technology. Work plan: -Potential key molecular mechanisms determining the course of RA and myositis are defined from genetic studies in humans, from relevant animal models and from basic cell and molecular biology. - Predictors of disease development and therapeutic responses, enabling future individualised therapies, are developed with the help of our unique large patient cohorts and, biobanks.. - Development and evaluation of new therapies is performed using combinations of novel molecular tools and precise definition of disease phenotypes. Impact of the project: We aim to produce (i) an increased understanding of the causes of RA and myositis enabling better prevention; (ii) new potential targets for therapy in arthritis and myositis, which can be further tested in other rheumatic inflammatory diseases; (iii) a prototype system for translational research in Europe, enabling collaborative development of targeted therapies in many inflammatory diseases and enabling European SMEs to rapidly develop ideas and patents into targeted therapies in inflammatory diseases.


Additional project information:   Project website 

Title: Genomics, mechanisms and treatment of addiction
Acronym:   GENADDICT
What's new:   New project
Project summary:   Addiction is a brain disease, common in Europe, with deleterious consequences on individual physical and psychological health, and serious societal and economic consequences through criminality and violence, decreased productivity and increased healthcare costs. In every family, in a lifetime one can identify someone who has suffered from addiction; alcohol, nicotine or illicit drug use affects many people. Over 20 years there has been little advance in the drug treatment for addiction, with most new treatments addressing physical drug withdrawal rather than treating drug craving and relapse. The contribution of genetic influences to addiction liability has been recently recognised but the identification of genetic risk factors and genes involved in the molecular basis of addiction is a new major challenge for the post-genomic era. This project is a collaboration between basic science groups, one SME and a leading biotechnology company devoted to human studies on the role of genes in complex diseases. This public-private partnership brings together a highly innovative genealogical led human genetics approach and a team of researchers with Europe¹s best genomic mouse models. The core of the research effort will be the identification of genes associated with drug addiction using an unbiased genome-wide approach. The strong environmental component in the etiology of drug addiction has presented a particularly difficult problem for genetic studies of this brain disorder in the past. The groups of this Consortium propose to meet this difficult challenge by combining powerful animal genetics and gene profiling strategies with a human genetic approach that is relatively resistant to environmental modifications of the drug addiction phenotype. Genes identified in this project will help to elucidate dysfunction of genetic pathways in the addicted brain and provide new targets for the development of novel therapies.

This integrated project started on 1 January 2005, and lasts 60 months. It involves 8 participants from 7 EU countries.


Additional project information:   Project website 

  NETWORKS OF EXCELLENCE (1)  
Title: Task-force in Europe for Drug Development for the Young
Acronym:   TEDDY
What's new:   New project
Project summary:   The Task-force in Europe for Drug Development for the Young (TEDDY) is a Network of Excellence funded under the Sixth EU Framework Programme for Research and Technological Development (FP6). The project started in June 2005 and is expected to run until 2010. It involves 17 partners from 9 EU countries, Romania and Israel. The overall aim of TEDDY is promoting the availability of safe and effective medicines for children in Europe by integrating existing expertise and good practices, as well as stimulating further developments. Today, no more than 30% of marketed drugs in Europe can be considered safe and effective with respect to their paediatric use, as a consequence of insufficient efforts in dedicated biomedical research. This gap is rooted, on the one hand, in the complexity of scientific and ethical issues linked to the design and execution of clinical trials involving children, and on the other hand, on a perception of poor profitability which seems to prevent pharmaceutical companies from investing significantly in this sector. However, along with other age groups, children as well should benefit from breakthroughs in genomics, biotechnology, pharmacology and therapeutics. The European Legislator is developing a Regulation on medicinal products for paediatric use which is likely to improve significantly the current situation. Within this general institutional framework, and in synergy with other processes and actors, TEDDY wishes to dwell on the development of a new research matrix that integrates scientific domains, assesses the impact of findings and monitors policy implementation. TEDDY aims at optimising the paediatric use of current drugs and promoting the development of new drugs.


Additional project information:   Project website 

Top